ArticlePhysiological reports2026
LL-37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Elevated LL-37 IgG levels are implicated in inflammatory conditions and immune complexes formed with LL-37 potentially propagate immunothrombosis in acute coronary syndrome (ACS). The reported binding of LL-37 to LDL may be relevant in this context given that LDL autoantibodies are implicated in ACS risk. In this report, three distinct cohorts were used to evaluate immunologic characteristics, clinical relevance, and potential mechanisms of elevated LL-37 IgG levels in ACS. First, evaluation of IgG reactive to native (n) LDL and LL-37 complexed with LDL (LL-37_LDL) in a cohort without acute disease demonstrated significantly higher levels of LL-37 IgG compared to LL-37_LDL IgG and nLDL IgG. Next, evaluation of LL-37 IgG levels in samples (N = 500) from the AZACS study (Azithromycin in ACS) and population-level associations with clinical characteristics showed that LL-37 IgG levels were significantly higher in subjects who had prior myocardial infarction and were negatively correlated with blood pressure. Third, an ACS cohort showed a negative association of LL-37 IgG with LVEF. There was also significantly reduced CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.